Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9893)	5/11/1999 8:50:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

Bluegreen, I thought Gary was being helpful by posting what ICOS board was saying about the sepsis efforts of ICOS. For a whole host of reasons, as the post indicated, this has been a difficult area for even trial design. XOMA attempts to address the issues with the meningo trial which treats children without, (we hope), other underlying diseases or health problems. And as the annual report makes clear addressing complications of blood loss that occur even before sepsis sets in. I know you know all this and am just posting because I got up early.